Legal Library: Search

In July 2020, the FTC required global suppliers of animal products, Elanco Animal Health, Inc. and Bayer Animal Health GmbH, to divest three animal health products to settle charges that Elanco’s proposed $7.6 billion acquisition of Bayer would likely be anticompetitive in those markets. On Sept. 11, 2020, the Commission announced the final consent agreement in this matter.

In April 2019, the FTC announced that a federal district court judge ordered Srinubabu Gedela and his companies to pay more than $50.1 million to resolve FTC charges that they made deceptive claims about the nature of their conferences and publications, and hid steep publication fees. The court ruling resolved a 2016 Commission complaint alleging that Gedela and the companies falsely advertised online scientific and medical academic journals and international conferences, and deceptively claimed the journals provided authors with rigorous peer review and editorial boards comprised of prominent academics.

Under a settlement with the Federal Trade Commission announced in March 2020, the marketers of an electrical nerve stimulation device called Quell have agreed to pay $4 million and stop making deceptive claims that the device treats pain throughout the body when placed below the knee. They also will stop claiming the device’s efficacy is clinically proven and that it has been cleared by the FDA to treat pain throughout the body. In early September 2020, the FTC announced it was returning almost $3.9 million to defrauded consumers.